Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by Rebecca Berhanu and Ian Sanne.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1,130
         
        
        
     
 
    
        
        - 
            Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
            
            
                Score: 0,536
             
- 
            Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
            
            
                Score: 0,155
             
- 
            The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
            
            
                Score: 0,107
             
- 
            High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
            
            
                Score: 0,038
             
- 
            Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
            
            
                Score: 0,037
             
- 
            Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review. Clin Infect Dis. 2017 10 01; 65(7):1226-1228.
            
            
                Score: 0,036
             
- 
            Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
            
            
                Score: 0,034
             
- 
            Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. J Int AIDS Soc. 2016; 19(1):20987.
            
            
                Score: 0,033
             
- 
            Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
            
            
                Score: 0,033
             
- 
            Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. Int J Tuberc Lung Dis. 2016 08; 20(8):1040-5.
            
            
                Score: 0,033
             
- 
            Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. Pan Afr Med J. 2015; 22:4.
            
            
                Score: 0,031
             
- 
            The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065.
            
            
                Score: 0,029
             
- 
            Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
            
            
                Score: 0,028